215 related articles for article (PubMed ID: 27232589)
1. Investigational drugs for treating agitation in persons with dementia.
Garay RP; Citrome L; Grossberg GT; Cavero I; Llorca PM
Expert Opin Investig Drugs; 2016 Aug; 25(8):973-83. PubMed ID: 27232589
[TBL] [Abstract][Full Text] [Related]
2. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.
Garay RP; Grossberg GT
Expert Opin Investig Drugs; 2017 Jan; 26(1):121-132. PubMed ID: 27936965
[TBL] [Abstract][Full Text] [Related]
3. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the treatment of agitation in Alzheimer's disease.
Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
[TBL] [Abstract][Full Text] [Related]
5. An update on the advancements in the treatment of agitation in Alzheimer's disease.
Porsteinsson AP; Antonsdottir IM
Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
[TBL] [Abstract][Full Text] [Related]
6. Investigational drugs in recent clinical trials for treatment-resistant depression.
Garay RP; Zarate CA; Charpeaud T; Citrome L; Correll CU; Hameg A; Llorca PM
Expert Rev Neurother; 2017 Jun; 17(6):593-609. PubMed ID: 28092469
[TBL] [Abstract][Full Text] [Related]
7. AXS-05: an investigational treatment for Alzheimer's disease-associated agitation.
Ward K; Citrome L
Expert Opin Investig Drugs; 2022 Aug; 31(8):773-780. PubMed ID: 35763451
[TBL] [Abstract][Full Text] [Related]
8. AVP-786 as a promising treatment option for Alzheimer's Disease including agitation.
Khoury R; Marx C; Mirgati S; Velury D; Chakkamparambil B; Grossberg GT
Expert Opin Pharmacother; 2021 May; 22(7):783-795. PubMed ID: 33615952
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
Kongpakwattana K; Sawangjit R; Tawankanjanachot I; Bell JS; Hilmer SN; Chaiyakunapruk N
Br J Clin Pharmacol; 2018 Jul; 84(7):1445-1456. PubMed ID: 29637593
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.
Garay RP; Citrome L; Samalin L; Liu CC; Thomsen MS; Correll CU; Hameg A; Llorca PM
Expert Opin Pharmacother; 2016; 17(7):921-36. PubMed ID: 26831200
[TBL] [Abstract][Full Text] [Related]
11. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
[TBL] [Abstract][Full Text] [Related]
12. Treatment of agitation in older persons with dementia. The Expert Concensus Panel for agitation in dementia.
Postgrad Med; 1998 Apr; Spec No():1-88. PubMed ID: 9585819
[No Abstract] [Full Text] [Related]
13. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
[TBL] [Abstract][Full Text] [Related]
14. Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia.
Med Lett Drugs Ther; 2023 Jun; 65(1679):99-101. PubMed ID: 37339089
[No Abstract] [Full Text] [Related]
15. When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
Aga VM
Am J Geriatr Psychiatry; 2019 Oct; 27(10):1099-1107. PubMed ID: 31288974
[TBL] [Abstract][Full Text] [Related]
16. The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.
Ward K; Citrome L
Expert Opin Investig Drugs; 2020 Mar; 29(3):245-257. PubMed ID: 32031021
[No Abstract] [Full Text] [Related]
17. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder.
Citrome L
Int J Clin Pract; 2012 Mar; 66(3):318-25. PubMed ID: 22226343
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
Lockwood JT; Remington G
Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic treatment of psychosis and agitation in the elderly.
Daniel DG
J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of current and novel drugs to treat agitation in Alzheimer's disease.
Herrmann N; Wang HJ; Song BX; Bawa KK; Lanctôt KL
Expert Opin Drug Saf; 2022 Oct; 21(10):1289-1301. PubMed ID: 36252087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
